Top

BMC Oral Health

Published in:

Open Access 01-12-2023 | Research

CDH4 inhibits ferroptosis in oral squamous cell carcinoma cells

Authors: Jian Xie, Ting Lan, Da-Li Zheng, Lin-Can Ding, You-Guang Lu

Published in: BMC Oral Health | Issue 1/2023

Abstract

Background

The cadherin-4 gene (CDH4), a member of the cadherin family genes, encodes R-cadherin (R-cad); however, the function of this gene in different types of cancer remains controversial. The function of CDH4 in OSCC (oral squamous cell carcinoma) is unknown.

Materials and methods

We use the Cancer Genome Atlas (TCGA) database to find the expression of CDH4 in OSCC is more than normal tissue. Our tissue samples also confirmed that CDH4 gene was highly expressed in OSCC. The related cell function assay detected that CDH4 promotes the ability of cell proliferation, migration, self-renewal and invasion. Cell staining experiment confirmed that the change of CDH4 expression would change the cell mortality. The western blot of GPX4 (glutathione-dependent peroxidase-4), GSH (reduced glutathione) test assay and MDA(Malondialdehyde) test assay show that the expression of CDH4 may resist the sensitivity of ferropotosis in OSCC.

Results

CDH4 was upregulated in OSCC samples and was correlation with poor survival of patients. High expression of CDH4 effectively promotes the proliferation, mobility of OSCC cells and reduce the sensitivity of OSCC cells to ferroptosis. CDH4 is positively correlated with EMT pathway genes, negatively correlated with fatty acid metabolism pathway genes and peroxisome pathway genes, and positively correlated with ferroptosis suppressor genes in OSCC.

Conclusions

These results indicate that CDH4 may play a positive role in tumor progression and resistance ferroptosis and may be a potential therapeutic target for OSCC.

Available only for authorised users

Kemler R. Classical cadherins. Semin Cell Biol. 1992;3(3):149–55. https://doi.org/10.1016/s1043-4682(10)80011-x. (PMID: 1623204).CrossRefPubMed

Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem. 1990;59:237–52. https://doi.org/10.1146/annurev.bi.59.070190.001321.CrossRefPubMed

Conacci-Sorrell M, Zhurinsky J, Ben-Ze’ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest. 2002;109(8):987–91. https://doi.org/10.1172/JCI15429.PMID:11956233;PMCID:PMC150951.

Goodsell DS. The molecular perspective: cadherin. Stem Cells. 2002;20(6):583–4. https://doi.org/10.1634/stemcells.20-6-583.CrossRefPubMed

Kaszak I, Witkowska-Piłaszewicz O, Niewiadomska Z, Dworecka-Kaszak B, Ngosa Toka F, Jurka P. Role of cadherins in cancer-a review. Int J Mol Sci. 2020;21(20):7624. https://doi.org/10.3390/ijms21207624.PMID:33076339;PMCID:PMC7589192.CrossRefPubMedPubMedCentral

Ebnet K, Kummer D, Steinbacher T, Singh A, Nakayama M, Matis M. Regulation of cell polarity by cell adhesion receptors. Semin Cell Dev Biol. 2018;81:2–12. https://doi.org/10.1016/j.semcdb.2017.07.032. (Epub 2017 Jul 22).CrossRefPubMed

Shahbazi MN, Perez-Moreno M. Connections between cadherin-catenin proteins, spindle misorientation, and cancer. Tissue Barriers. 2015;3(3).

Casal JI, Bartolomé RA. Beyond N-cadherin, relevance of cadherins 5, 6 and 17 in cancer progression and metastasis. Int J Mol Sci. 2019;20(13):3373. https://doi.org/10.3390/ijms20133373.CrossRefPubMedPubMedCentral

Li Y, Lv Z, Zhang S, et al. Genetic fate mapping of transient cell fate reveals N-cadherin activity and function in tumor metastasis. Dev Cell. 2020;54(5):593-607.e5. https://doi.org/10.1016/j.devcel.2020.06.021. (Epub 2020 Jul 14).CrossRefPubMed

10.

Mendonsa AM, Na TY, Gumbiner BM. E-cadherin in contact inhibition and cancer. Oncogene. 2018;37(35):4769–80. https://doi.org/10.1038/s41388-018-0304-2. (Epub 2018 May 21).CrossRefPubMedPubMedCentral

11.

Hugo HJ, Gunasinghe NPAD, Hollier BG, et al. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin. Breast Cancer Res. 2017;19(1):86. https://doi.org/10.1186/s13058-017-0880-z.CrossRefPubMedPubMedCentral

12.

Delgado-Bellido D, Serrano-Saenz S, Fernández-Cortés M, et al. Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin. Mol Cancer. 2017;16(1):65. https://doi.org/10.1186/s12943-017-0631-x.CrossRefPubMedPubMedCentral

13.

Babb SG, Kotradi SM, Shah B, et al. Zebrafish R-cadherin (Cdh4) controls visual system development and differentiation. Dev Dyn. 2005;233(3):930–45. https://doi.org/10.1002/dvdy.20431.CrossRefPubMed

14.

Rosenberg P, Esni F, Sjödin A, et al. A potential role of R-cadherin in striated muscle formation. Dev Biol. 1997;187(1):55–70. https://doi.org/10.1006/dbio.1997.8602.CrossRefPubMed

15.

Dahl U, Sjödin A, Larue L, et al. Genetic dissection of cadherin function during nephrogenesis. Mol Cell Biol. 2002;22(5):1474–87. https://doi.org/10.1128/MCB.22.5.1474-1487.2002.CrossRefPubMedPubMedCentral

16.

Wiszniewski W, Gawlinski P, Gambin T, et al. Comprehensive genomic analysis of patients with disorders of cerebral cortical development. Eur J Hum Genet. 2018;26(8):1121–31. https://doi.org/10.1038/s41431-018-0137-z. (Epub 2018 Apr 30).CrossRefPubMedPubMedCentral

17.

Lin J, Wang C, Redies C. Restricted expression of classic cadherins in the spinal cord of the chicken embryo. Front Neuroanat. 2014;31(8):18. https://doi.org/10.3389/fnana.2014.00018.CrossRef

18.

Du C, Huang T, Sun D, et al. CDH4 as a novel putative tumor suppressor gene epigenetically silenced by promoter hypermethylation in nasopharyngeal carcinoma. Cancer Lett. 2011;309(1):54–61. https://doi.org/10.1016/j.canlet.2011.05.016. (Epub 2011 Jun 12).CrossRefPubMed

19.

Xie J, Feng Y, Lin T, Huang XY, et al. CDH4 suppresses the progression of salivary adenoid cystic carcinoma via E-cadherin co-expression. Oncotarget. 2016;7(50):82961–71. https://doi.org/10.18632/oncotarget.12821.CrossRefPubMedPubMedCentral

20.

Li Z, Su D, Ying L, et al. Study on expression of CDH4 in lung cancer. World J Surg Oncol. 2017;15(1):26. https://doi.org/10.1186/s12957-016-1083-2.CrossRefPubMedPubMedCentral

21.

Agiostratidou G, Li M, Suyama K, et al. Loss of retinal cadherin facilitates mammary tumor progression and metastasis. Cancer Res. 2009;69(12):5030–8. https://doi.org/10.1158/0008-5472.CAN-08-4007. (Epub 2009 Jun 2).CrossRefPubMedPubMedCentral

22.

Miotto E, Sabbioni S, Veronese A, et al. Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res. 2004;64(22):8156–9. https://doi.org/10.1158/0008-5472.CAN-04-3000.CrossRefPubMed

23.

Ceresa D, Alessandrini F, Bosio L, et al. Cdh4 Down-Regulation Impairs in Vivo Infiltration and Malignancy in Patients Derived Glioblastoma Cells. Int J Mol Sci. 2019;20(16):4028. https://doi.org/10.3390/ijms20164028.CrossRefPubMedPubMedCentral

24.

Kucharczak J, Charrasse S, Comunale F, et al. R-Cadherin expression inhibits myogenesis and induces myoblast transformation via Rac1 GTPase. Cancer Res. 2008;68(16):6559–68. https://doi.org/10.1158/0008-5472.CAN-08-0196.CrossRefPubMed

25.

Zhou X, Huang H, Cui W, et al. Expression and Prognostic Significance of Cadherin 4 (CDH4) in Renal Cell Carcinoma. Med Sci Monit. 2020;26:e922836.CrossRefPubMedPubMedCentral

26.

Johnson E, Theisen CS, Johnson KR, et al. R-cadherin influences cell motility via Rho family GTPases. J Biol Chem. 2004 Jul 23;279(30):31041–9. doi: https://doi.org/10.1074/jbc.M400024200. Epub 2004 May 13. Erratum in: J Biol Chem. 2004 Oct 15;279(42):44230.

27.

Tang Q, Lu J, Zou C, et al. CDH4 is a novel determinant of osteosarcoma tumorigenesis and metastasis. Oncogene. 2018;37(27):3617–30. https://doi.org/10.1038/s41388-018-0231-2. (Epub 2018 Apr 3).CrossRefPubMed

28.

Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. https://doi.org/10.1016/j.cell.2012.03.042.CrossRefPubMedPubMedCentral

29.

Gan B. Mitochondrial regulation of ferroptosis. J Cell Biol. 2021;220(9):e202105043.CrossRefPubMedPubMedCentral

30.

Zhao L, Zhou X, Xie F, Zhang L, Yan H, Huang J, Zhang C, Zhou F, Chen J, Zhang L. Ferroptosis in cancer and cancer immunotherapy. Cancer Commun (Lond). 2022;42(2):88–116. https://doi.org/10.1002/cac2.12250.CrossRefPubMedPubMedCentral

31.

Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381–96. https://doi.org/10.1038/s41568-022-00459-0. (Epub 2022 Mar 25).CrossRefPubMed

32.

Hassannia B, Vandenabeele P, Vanden BT. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35(6):830–49. https://doi.org/10.1016/j.ccell.2019.04.002. (Epub 2019 May 16).CrossRefPubMed

33.

Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34. https://doi.org/10.1186/s13045-019-0720-y.CrossRefPubMedPubMedCentral

34.

Yu H, Guo P, Xie X, et al. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med. 2017;21(4):648–57. https://doi.org/10.1111/jcmm.13008. (Epub 2016 Nov 10).CrossRefPubMed

35.

Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1):47. https://doi.org/10.1186/s12943-022-01530-y.CrossRefPubMedPubMedCentral

36.

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660. (Epub 2021 Feb 4).CrossRefPubMed

37.

Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi: https://doi.org/10.3322/caac.21654. Epub 2021 Jan 12. Erratum in: CA Cancer J Clin. 2021;71(4):359.

38.

Taghavi N, Yazdi I. Prognostic factors of survival rate in oral squamous cell carcinoma: clinical, histologic, genetic and molecular concepts. Arch Iran Med. 2015;18(5):314–9.PubMed

39.

Ford PJ, Rich AM. Tobacco use and oral health. Addiction. 2021;116(12):3531–40. https://doi.org/10.1111/add.15513. (Epub 2021 Apr 25).CrossRefPubMed

40.

Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet. 2008;371(9625):1695–709. https://doi.org/10.1016/S0140-6736(08)60728-X.CrossRefPubMedPubMedCentral

41.

von Witzleben A, Wang C, Laban S, Savelyeva N, Ottensmeier CH. HNSCC: tumour antigens and their targeting by immunotherapy. Cells. 2020;9(9):2103. https://doi.org/10.3390/cells9092103.CrossRef

42.

Lindemann A, Takahashi H, Patel AA, et al. Targeting the DNA damage response in OSCC with TP53 mutations. J Dent Res. 2018;97(6):635–44. https://doi.org/10.1177/0022034518759068. (Epub 2018 Feb 28).CrossRefPubMedPubMedCentral

43.

Huang WC, Jang TH, Tung SL, et al. A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing β5-integrin/c-met signaling pathway. J Exp Clin Cancer Res. 2019;38(1):89. https://doi.org/10.1186/s13046-019-1091-5.CrossRefPubMedPubMedCentral

44.

Polizzi A, Santonocito S, Lo Giudice A, Alibrandi A, De Pasquale R, Isola G. Analysis of the response to two pharmacological protocols in patients with oral lichen planus: A randomized clinical trial. Oral Dis. 2023;29(2):755–63. https://doi.org/10.1111/odi.13960. (Epub 2021 Jul 29 PMID: 34252252).CrossRefPubMed

45.

Lodi G, Franchini R, Warnakulasuriya S, Varoni EM, Sardella A, Kerr AR, Carrassi A, MacDonald LC, Worthington HV. Interventions for treating oral leukoplakia to prevent oral cancer. Cochrane Database Syst Rev. 2016;7(7):CD001829.PubMed

46.

Isola G, Matarese M, Ramaglia L, Iorio-Siciliano V, Cordasco G, Matarese G. Efficacy of a drug composed of herbal extracts on postoperative discomfort after surgical removal of impacted mandibular third molar: a randomized, triple-blind, controlled clinical trial. Clin Oral Investig. 2019;23(5):2443–53. https://doi.org/10.1007/s00784-018-2690-9. (Epub 2018 Oct 11 PMID: 30311061).CrossRefPubMed

47.

Li H, Zhang Y, Xu M, Yang D. Current trends of targeted therapy for oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2022;148(9):2169–86. https://doi.org/10.1007/s00432-022-04028-8. (Epub 2022 May 2 PMID: 35501496).CrossRefPubMed

48.

Sinto MS, Thomas S, Kannan S. Combinatorial treatment with Gefitinib and Bay11-7085 sensitizes primary Gefitinib-resistant OSCC cells by influencing the EGFR- NFκB signaling axis. Med Oncol. 2021;38(9):110. https://doi.org/10.1007/s12032-021-01557-z.CrossRefPubMed

49.

Ohnishi Y, Yasui H, Nozaki M, et al. Molecularly-targeted therapy for the oral cancer stem cells. Jpn Dent Sci Rev. 2018;54(2):88–103. https://doi.org/10.1016/j.jdsr.2017.11.001. (Epub 2017 Dec 16).CrossRefPubMed

50.

Wang J, Chen X, Tian Y, et al. Six-gene signature for predicting survival in patients with head and neck squamous cell carcinoma. Aging (Albany NY). 2020;12(1):767–83. https://doi.org/10.18632/aging.102655.CrossRefPubMed

51.

Kajarabille N, Latunde-Dada GO. Programmed cell-death by ferroptosis: antioxidants as mitigators. Int J Mol Sci. 2019;20(19):4968. https://doi.org/10.3390/ijms20194968.CrossRefPubMedPubMedCentral

52.

Dahlmanns M, Yakubov E, Dahlmanns JK. Genetic profiles of ferroptosis in malignant brain tumors and off-target effects of ferroptosis induction. Front Oncol. 2021;11:783067.

53.

Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic Biol Med. 2020;20(152):175–85. https://doi.org/10.1016/j.freeradbiomed.2020.02.027. (Epub 2020 Mar 9).CrossRef

54.

Gleber-Netto FO, Braakhuis BJ, Triantafyllou A, Takes RP, Kelner N, Rodrigo JP, Strojan P, Vander Poorten V, Rapidis AD, Rinaldo A, Brakenhoff RH, Ferlito A, Kowalski LP. Molecular events in relapsed oral squamous cell carcinoma: recurrence vs. secondary primary tumor. Oral Oncol. 2015;51(8):738–44.CrossRefPubMed

55.

Liu CH, Chen HJ, Wang PC, Chen HS, Chang YL. Patterns of recurrence and second primary tumors in oral squamous cell carcinoma treated with surgery alone. Kaohsiung J Med Sci. 2013;29(10):554–9. https://doi.org/10.1016/j.kjms.2013.03.001. (Epub 2013 Jun 7 PMID: 24099110).CrossRefPubMed

56.

Pastushenko I, Blanpain C. EMT Transition States during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26. https://doi.org/10.1016/j.tcb.2018.12.001. (Epub 2018 Dec 26).CrossRefPubMed

57.

Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40(18):e108647.CrossRefPubMedPubMedCentral

58.

Recouvreux MS, Miao J, Gozo MC, Wu J, Walts AE, Karlan BY, Orsulic S. FOXC2 promotes vasculogenic mimicry in ovarian cancer. Cancers (Basel). 2022;14(19):4851. https://doi.org/10.3390/cancers14194851.CrossRefPubMed

59.

Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY. The E-Cadherin and N-Cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):1118. https://doi.org/10.3390/cells8101118.CrossRefPubMedPubMedCentral

60.

Qi Y, Xu R. Roles of PLODs in collagen synthesis and cancer progression. Front Cell Dev Biol. 2018;28(6):66. https://doi.org/10.3389/fcell.2018.00066.CrossRef

61.

Tian S, Xu X, Yang X, Fan L, Jiao Y, Zheng M, Zhang S. Roles of follistatin-like protein 3 in human non-tumor pathophysiologies and cancers. Front Cell Dev Biol. 2022;10:953551.CrossRefPubMedPubMedCentral

62.

Liu S, Yu Y, Wang Y, Zhu B, Han B. COLGALT1 is a potential biomarker for predicting prognosis and immune responses for kidney renal clear cell carcinoma and its mechanisms of ceRNA networks. Eur J Med Res. 2022;27(1):122. https://doi.org/10.1186/s40001-022-00745-5.CrossRefPubMedPubMedCentral

63.

Li J, Chen C, Chen B, Guo T. High FN1 expression correlates with gastric cancer progression. Pathol Res Pract. 2022;239:154179.CrossRefPubMed

64.

Qiu D, Hu J, Hu J, Yu A, Othmane B, He T, Ding J, Cheng X, Ren W, Tan X, Yu Q, Chen J, Zu X. PMEPA1 is a prognostic biomarker that correlates with cell malignancy and the tumor microenvironment in bladder cancer. Front Immunol. 2021;12:705086.

65.

Sun H, Zhang H, Yan Y, Li Y, Che G, Zhou C, Nicot C, Ma H. NCAPG promotes the oncogenesis and progression of non-small cell lung cancer cells through upregulating LGALS1 expression. Mol Cancer. 2022;21(1):55. https://doi.org/10.1186/s12943-022-01533-9.Erratum.In:MolCancer.2022Dec14;21(1):221.CrossRefPubMedPubMedCentral

66.

JingSong H, Hong G, Yang J, Duo Z, Li F, WeiCai C, XueYing L, YouSheng M, YiWen O, Yue P, Zou C. siRNA-mediated suppression of collagen type iv alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration. Oncotarget. 2017;8(2):2585–93. https://doi.org/10.18632/oncotarget.13716.CrossRefPubMed

67.

Tian S, Peng P, Li J, Deng H, Zhan N, Zeng Z, Dong W. SERPINH1 regulates EMT and gastric cancer metastasis via the Wnt/β-catenin signaling pathway. Aging (Albany NY). 2020;12(4):3574–93. https://doi.org/10.18632/aging.102831. (Epub 2020 Feb 24).CrossRefPubMed

68.

Sun LR, Li SY, Guo QS, Zhou W, Zhang HM. SPOCK1 involvement in epithelial-to-mesenchymal transition: a new target in cancer therapy? Cancer Manag Res. 2020;18(12):3561–9. https://doi.org/10.2147/CMAR.S249754.CrossRef

69.

Lee J, You JH, Kim MS, et al. Epigenetic reprogramming of epithelial-mesenchymal transition promotes ferroptosis of head and neck cancer. Redox Biol. 2020 Oct; 37:101697. doi: https://doi.org/10.1016/j.redox.2020.101697. Epub 2020 Aug 28.

70.

Rand D, Ravid O, Atrakchi D, et al. Endothelial iron homeostasis regulates blood-brain barrier integrity via the HIF2α-Ve-Cadherin pathway. Pharmaceutics. 2021;13(3):311. https://doi.org/10.3390/pharmaceutics13030311.CrossRefPubMedPubMedCentral

Title: CDH4 inhibits ferroptosis in oral squamous cell carcinoma cells
Authors: Jian Xie
Ting Lan
Da-Li Zheng
Lin-Can Ding
You-Guang Lu
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: BMC Oral Health / Issue 1/2023
Electronic ISSN: 1472-6831
DOI: https://doi.org/10.1186/s12903-023-03046-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

CDH4 inhibits ferroptosis in oral squamous cell carcinoma cells

Abstract

Background

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Experimental periodontitis induced hypoadiponectinemia by IRE1α-mediated endoplasmic reticulum stress in adipocytes

Dental caries status and its associated factors among schoolchildren aged 6–8 years in Hangzhou, China: a cross-sectional study

Oridonin alleviates the inhibitory effect of lipopolysaccharide on the proliferation and osteogenic potential of periodontal ligament stem cells by inhibiting endoplasmic reticulum stress and NF-κB/NLRP3 inflammasome signaling

Effect of the computer-aided static navigation technique on the accuracy of bicortical mini-implants placement site for maxillary skeletal expansion appliances: an in vitro study

Characteristics of dentists and patients associated with appropriate antibiotic prescriptions by French dentists: a cross-sectional study using Health Insurance databases

Sense of coherence in a general adult population in Northern Norway and its associations with oral health